Aprogen

Unparalleled biopharmaceutical innovation

Seongnam, South Korea · Founded 2000 · $26.7M raised

Headquarters
Seongnam
Employees
201–500
Founded
2000
Business Model
B2B
Total Funding
$26.7M
Last Round
$10.0M Private EquityMay 2026
Rounds
3

About

Aprogen, founded in 2000 and headquartered in Seongnam, South Korea, is a biopharmaceutical company focused on biosimilar development and manufacturing. The company developed South Korea's first approved antibody biosimilar in 2006 and has since expanded its pipeline to include biosimilars for infliximab, trastuzumab, adalimumab, rituximab, and cetuximab, as well as novel bispecific antibody therapeutics. Aprogen is listed on the KOSPI exchange.

Summary

Aprogen is a Biotech company based in Seongnam, South Korea, founded in 2000. It has raised $26.7M in total across 3 rounds, most recently a $10.0M Private Equity round in May 2026.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Private EquityPrivate EquityMay 2026
$10.0M

Sign up to see all 3 rounds

Seed through Private Equity — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Aprogen on Indexed.vc
<a href="https://indexed.vc/companies/aprogen"><img src="https://indexed.vc/api/badge/company/aprogen" alt="Aprogen on Indexed.vc" width="260" height="76" /></a>